Trade CTOR anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Citius Oncology, Inc. (CTOR) is trading at US$0.78, down 1.30% today as of Aug 28, 12:28 EDT. The company has a market capitalisation of US$78.66M. Over the past 52 weeks, CTOR has traded between US$0.49 and US$2.25. On Syfe you can trade CTOR with $0 commission and add it to your watchlist.
| Previous close | US$0.79 |
|---|---|
| Market cap | US$78.66M |
| P/E ratio | 19.34 |
| 52-week range | US$0.49 – US$2.25 |
| Volume | 8.16K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Citius Oncology, Inc.
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.
Year: 2024
Citius Oncology, Inc. (CTOR) stock is trading at US$0.78, -1.30% from the previous close of US$0.79.
The market cap for Citius Oncology, Inc. (CTOR) stock is approximately US$78.66M.
The price-to-earnings ratio for Citius Oncology, Inc. (CTOR) is 19.34, based on the latest reported earnings.
The 52-week high for Citius Oncology, Inc. (CTOR) stock is US$2.25.
The 52-week low for Citius Oncology, Inc. (CTOR) stock is US$0.49.
Citius Oncology, Inc. (CTOR) does not currently pay a dividend.
Stay on top of CTOR
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
